Drugs for Mitochondrial Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 33)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bezafibrate |
Approved, Investigational |
Phase 2 |
|
41859-67-0 |
39042 |
Synonyms:
2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid
2-(P-(2-(P-chlorobenzamido)Ethyl)phenoxy)-2-methylpropionate
2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
2-(P-(2-(P-chlorobenzamido)Ethyl)phenoxy)-2-methylpropionic acid
2-[4-(2-[4-Chlorobenzamido]ethyl)- phenoxy]-2-methylpropanoic acid
2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid
2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
41859-67-0
a-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid
AB00052265
AB1004588
AC1L20XS
AC1Q5E4V
AC-6817
AKOS005107743
Azufibrat
Azupharma brand OF bezafibrate
Azupharma Brand of Bezafibrate
B3346
B7273_SIGMA
Bayer brand OF bezafibrate
Bayer Brand of Bezafibrate
Befibrat
Befizal
Béfizal
Berlin chemie brand OF bezafibrate
Berlin Chemie Brand of Bezafibrate
Berlin-chemie brand OF bezafibrate
Berlin-Chemie Brand of Bezafibrate
Betapharm brand OF bezafibrate
Betapharm Brand of Bezafibrate
Beza lande
Beza Lande
Beza puren
Beza Puren
Bezabeta
Bezacur
Bezafibrat
Bezafibrat PB
bezafibrate
Bezafibrate
Bezafibrate (JP15/USAN/INN)
Bezafibrate [USAN:BAN:INN:JAN]
Bezafibrate azupharma brand
Bezafibrate Azupharma Brand
Bezafibrate bayer brand
Bezafibrate Bayer Brand
Bezafibrate berlin-chemie brand
Bezafibrate Berlin-Chemie Brand
Bezafibrate betapharm brand
Bezafibrate Betapharm Brand
Bezafibrate cryopharma brand
Bezafibrate Cryopharma Brand
Bezafibrate elfar brand
Bezafibrate Elfar Brand
Bezafibrate hennig brand
Bezafibrate Hennig Brand
Bezafibrate hexal brand
Bezafibrate Hexal Brand
Bezafibrate isis brand
Bezafibrate Isis Brand
Bezafibrate lakeside brand
Bezafibrate Lakeside Brand
Bezafibrate merckle brand
Bezafibrate Merckle Brand
Bezafibrate roche brand
Bezafibrate Roche Brand
Bezafibrate synthelabo brand
Bezafibrate Synthelabo Brand
Bezafibrate tad brand
Bezafibrate TAD Brand
Bezafibrate teva brand
Bezafibrate Teva Brand
Bezafibrato
Bezafibrato [INN-Spanish]
Bezafibrato [Spanish]
Bezafibratum
Bezafibratum [INN-Latin]
Bezafibric acid
Bezafisal
Beza-lande
BezaLande
Beza-Lande
Bezalip
Bezalip Retard
Bezamerck
Beza-puren
BezaPuren
Beza-Puren
Bezatol
Bezatol SR
Bezatol SR (TN)
BF-759
Bio2_000034
Bio2_000514
BM 15.075
BM 15075
BM15.075
BM-15.075
BM-15075
Boehringer mannheim brand OF bezafibrate
Boehringer Mannheim Brand of Bezafibrate
BPBio1_000589
BRD-K46018455-001-06-0
BRN 4267656
|
BSPBio_000535
BSPBio_001314
BSPBio_003119
C19H20ClNO4
CAS-41859-67-0
CCRIS 9085
Cedur
CHEBI:47612
CHEMBL264374
CID39042
Cryopharma brand OF bezafibrate
Cryopharma Brand of Bezafibrate
D001629
D01366
DB01393
DB08380
Difaterol
DivK1c_000092
durabezur
Durabezur
EINECS 255-567-9
Elfar brand OF bezafibrate
Elfar Brand of Bezafibrate
Eulitop
Hennig brand OF bezafibrate
Hennig Brand of Bezafibrate
Hexal brand OF bezafibrate
Hexal Brand of Bezafibrate
HMS1361B16
HMS1569K17
HMS1791B16
HMS1921H16
HMS1989B16
HMS2089F04
HMS2092B12
HMS500E14
I06-1311
IDI1_000092
IDI1_033784
Isis brand OF bezafibrate
Isis Brand of Bezafibrate
KBio1_000092
KBio2_000034
KBio2_001923
KBio2_002602
KBio2_004491
KBio2_005170
KBio2_007059
KBio3_000067
KBio3_000068
KBio3_002619
KBioGR_000034
KBioGR_000669
KBioSS_000034
KBioSS_001923
Lakeside brand OF bezafibrate
Lakeside Brand of Bezafibrate
Lipox
LO 44
LS-124535
Merckle brand OF bezafibrate
Merckle Brand of Bezafibrate
MLS000028533
MLS001148205
MolPort-001-738-424
NCGC00016850-01
NCGC00016850-02
NCGC00016850-11
NCGC00023317-03
NCGC00023317-04
NCGC00023317-05
NCGC00023317-06
NCGC00023317-07
NCGC00023317-08
NINDS_000092
PB, Bezafibrat
Prestwick_724
Prestwick0_000378
Prestwick1_000378
Prestwick2_000378
Prestwick3_000378
Reducterol
Regadrin b
Regadrin B
Roche brand OF bezafibrate
Roche Brand of Bezafibrate
Sklerofibrat
SMR000058298
Solibay
SPBio_000824
SPBio_002456
Spectrum_001443
SPECTRUM1502046
Spectrum2_000922
Spectrum3_001500
Spectrum4_000325
Spectrum5_001079
Spectrum5_001967
ST51014927
synthelabo Brand OF bezafibrate
Synthelabo Brand of Bezafibrate
TAD brand OF bezafibrate
TAD Brand of Bezafibrate
Teva brand OF bezafibrate
Teva Brand of Bezafibrate
|
|
2 |
|
Nicotinamide |
Approved, Investigational |
|
|
98-92-0 |
936 |
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
37321-14-5
3-Carbamoylpyridine
3-pyridinecarboxamide
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC1L1ACZ
AC1Q4ZFV
AC-907/25014114
Acid amide
AI3-02906
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Astra Brand of Niacinamide
Austrovit PP
b 3, Vitamin
B 3, Vitamin
b3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
beta-Pyridinecarboxamide
bmse000281
b-Pyridinecarboxamide
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
Factor PP
Hansamid
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
Jenapharm, nicotinsäureamid
LS-2051
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
Merck Brand of Niacinamide
MLS000069714
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
Nandervit-N
NCGC00093354-03
NCGC00093354-04
nchembio.154-comp4
nchembio.73-comp6
Niacevit
Niacin
niacin - Vitamin B3
niacinamide
Niacinamide
Niacinamide (USP)
Niacinamide [USAN]
|
Niacinamide astra brand
Niacinamide Astra Brand
Niacinamide jenapharm brand
Niacinamide Jenapharm Brand
Niacinamide merck brand
Niacinamide Merck Brand
Niacinamide pharmagenix brand
Niacinamide Pharmagenix Brand
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
nicotinamide
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid [German]
Nicotinsaureamid Jenapharm
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
niko-Tamin
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
NSC 13128
NSC13128
NSC27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
Pharmagenix Brand of Niacinamide
PP-Faktor
Propamine a
pyridine-3-carboxamide
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
Savacotyl
SGCUT00176
SMR000058212
to_000073
UNII-25X51I8RD4
Vi-nicotyl
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin b 3
Vitamin B 3
Vitamin b3
Vitamin H1
vitamin PP
Vitamin PP
Witamina PP
WLN: T6NJ CVZ
ZINC00005878
β-pyridinecarboxamide
|
|
3 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
|
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
4 |
|
Niacin |
Approved, Investigational, Nutraceutical |
|
|
59-67-6 |
938 |
Synonyms:
3 Pyridinecarboxylic acid
3-Carboxylpyridine
3-carboxypyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
Acide nicotinique
acido Nicotinico
ácido nicotínico
Acidum nicotinicum
Acidum Nicotinicum
Akotin
Aluminum salt, niacin
anti-pellagra vitamin
Anti-pellagra vitamin
Apelagrin
beta-Pyridinecarboxylate
beta-Pyridinecarboxylic acid
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
Daskil
Efacin
Enduracin
Hydrochloride, niacin
Induracin
Linic
Lithium nicotinate
m-Pyridinecarboxylate
m-pyridinecarboxylic acid
m-Pyridinecarboxylic acid
Niac
Niacin
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
|
Niacin tosylate
Niacin zinc salt
Niacina
Niacine
Niacor
Nicacid
Nicamin
Nicangin
nico 400
nico-400
Nico400
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
nico-Span
Nicotinate
Nicotinate, lithium
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nikotinsäure
Nyclin
P.P. factor
Pellagra preventive factor
Pellagrin
Pelonin
Potassium salt, niacin
PP Factor
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
Pyridine-beta-carboxylic acid
Pyridine-β-carboxylate
pyridine-β-carboxylic acid
Pyridine-β-carboxylic acid
slo-Niacin
Sodium salt, niacin
Tartrate, niacin
Tosylate, niacin
Vitamin b3
Wampocap
β-pyridinecarboxylate
β-pyridinecarboxylic acid
|
|
5 |
|
Coenzyme Q10 |
Approved, Investigational, Nutraceutical |
|
|
303-98-0 |
5281915 |
Synonyms:
(all-e)-2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione
(all-e)-2,3-Dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-cyclohexadiene-1,4-dione
2-((all-e)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-P-benzoquinone
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-P-benzoquinone
2,3-Dimethoxy-5-methyl-6-decaprenylbenzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-cyclohexadiene-1,4-dione
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone
4-Ethyl-5-fluoropyrimidine
Adelir
all-trans-Ubiquinone
Aqua Q 10l10
Aqua Q10
bio-Quinon
bio-Quinone Q10
Coenzyme Q10
Coenzyme Q-10
CO-Enzyme Q10
Coenzyme Q10, (Z,Z,Z,Z,Z,Z,e,e,e)-isomer
Coenzyme Q10, ion (1-), (all-e)-isomer
CoQ
CoQ 10
CoQ10
Ensorb
Kaneka Q10
|
Kudesan
Li-Q-sorb
Liquid-Q
Neuquinon
Neuquinone
PureSorb Q 40
Q
Q 10AA
Q 199
Q10
Q-Gel
Q-Gel 100
Q-Ter
Ubidecarenone
Ubiquinone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
UBIQUINONE-10
Ubisemiquinone
Ubisemiquinone radical
Unbiquinone
Unispheres Q 10
|
|
6 |
|
Resveratrol |
Investigational |
|
|
501-36-0 |
445154 |
Synonyms:
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(e)-Resveratrol
(E)-resveratrol
3,4',5-Stilbenetriol
3,4',5-trihydroxystilbene
3,4',5-Trihydroxystilbene
3,4',5-trihydroxy-trans-stilbene
3,4',5-Trihydroxy-trans-stilbene
3,5,4'-trihydroxystilbene
|
3,5,4'-Trihydroxystilbene
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol
5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
cis-Resveratrol
Resveratrol-3-sulfate
SRT 501
SRT-501
trans-3,4',5 - Trihydroxystilbene
trans-resveratrol
trans-Resveratrol
|
|
7 |
|
carnitine |
|
|
|
|
|
8 |
|
Alpha-lipoic Acid |
|
|
|
|
|
9 |
|
Antioxidants |
|
|
|
|
|
10 |
|
Thioctic Acid |
|
|
|
|
|
11 |
|
Protective Agents |
|
|
|
|
|
12 |
|
Analgesics, Non-Narcotic |
|
|
|
|
|
13 |
|
Analgesics |
|
|
|
|
|
14 |
|
Platelet Aggregation Inhibitors |
|
|
|
|
|
15 |
|
Anti-Inflammatory Agents |
|
|
|
|
|
16 |
|
Antirheumatic Agents |
|
|
|
|
|
17 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
|
|
|
|
18 |
|
pyruvate |
|
|
|
|
|
19 |
|
Micronutrients |
|
|
|
|
|
20 |
|
Vitamin B Complex |
|
|
|
|
|
21 |
|
Vitamins |
|
|
|
|
|
22 |
|
Nutrients |
|
|
|
|
|
23 |
|
Folate |
|
|
|
|
|
24 |
|
Trace Elements |
|
|
|
|
|
25 |
|
Vitamin B9 |
|
|
|
|
|
26 |
|
Hypolipidemic Agents |
|
|
|
|
|
27 |
|
Lipid Regulating Agents |
|
|
|
|
|
28 |
|
Antimetabolites |
|
|
|
|
|
29 |
|
Nicotinic Acids |
|
|
|
|
|
30 |
|
Vitamin B3 |
|
|
|
|
|
31 |
|
Vasodilator Agents |
|
|
|
|
|
32 |
|
Ubiquinone |
|
|
|
|
|
33 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
|
|
|
|
Interventional clinical trials:
(show all 30)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension |
Terminated |
NCT03323749 |
Phase 3 |
|
2 |
Exercise Training and Deconditions: Implications for Therapy in Mitochondrial Myopathy |
Unknown status |
NCT00457314 |
Phase 2 |
|
3 |
Investigation of Clinical Syndromes Associated With mtDNA Point Mutations: MELAS/DCA Clinical Trial |
Unknown status |
NCT00068913 |
Phase 2 |
Dichloroacetate |
4 |
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR) |
Completed |
NCT02255422 |
Phase 2 |
Omaveloxolone capsules, 2.5 mg;omaveloxolone capsules, 5 mg;omaveloxolone capsules, 10 mg;Placebo capsules;omaveloxolone capsules, 20 mg;omaveloxolone capsules, TBD mg;omaveloxolone capsules, 40 mg;omaveloxolone capsules, 80 mg;omaveloxolone capsules, 160 mg |
5 |
A Feasibility Study of Bezafibrate in Mitochondrial Myopathy |
Completed |
NCT02398201 |
Phase 2 |
Bezafibrate |
6 |
Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease |
Completed |
NCT02367014 |
Phase 1, Phase 2 |
elamipretide (low dose);elamipretide (intermediate dose);elamipretide (high dose);Placebo |
7 |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study |
Completed |
NCT02805790 |
Phase 2 |
Elamipretide;Placebo |
8 |
An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease |
Completed |
NCT02909400 |
Phase 2 |
KH176;placebo |
9 |
A Phase IIb Double-blind, Randomised, Placebo-controlled, Multi-centre, Confirmative Three-way Cross-over Study on Cognitive Function With Two Doses of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation. |
Recruiting |
NCT04165239 |
Phase 2 |
KH176;KH176;Placebo |
10 |
A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM) |
Terminated |
NCT02976038 |
Phase 2 |
elamipretide |
11 |
A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease |
Recruiting |
NCT03888716 |
Phase 1 |
KL1333;Placebo Oral Tablet |
12 |
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment |
Active, not recruiting |
NCT03862846 |
Phase 1 |
REN001 |
13 |
Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies |
Unknown status |
NCT03513835 |
|
|
14 |
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy |
Completed |
NCT01301235 |
|
|
15 |
Nutritional Assessment in Patients Affected by Mitochondrial Cytopathy |
Completed |
NCT02375438 |
|
|
16 |
Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy |
Completed |
NCT00004770 |
|
thioctic acid |
17 |
Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders: A Double-blind, Placebo-controlled, Cross Over Study |
Completed |
NCT03728777 |
|
|
18 |
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia |
Completed |
NCT00004353 |
|
|
19 |
The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients |
Completed |
NCT03973203 |
|
|
20 |
A Prospective Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300) |
Completed |
NCT03048617 |
|
|
21 |
Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy |
Completed |
NCT02385565 |
|
|
22 |
GDF-15 as a Biomarker for Mitochondrial Disease |
Completed |
NCT02745938 |
|
|
23 |
Safety and Efficacy of Aerobic Exercise Training in Barth Syndrome |
Completed |
NCT01194141 |
|
|
24 |
Evaluation of Oxidative Capacity and Exercise Tolerance in Ambulatory Patients With Spinal Muscular Atrophy (SMA) |
Recruiting |
NCT02895789 |
|
|
25 |
Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies |
Recruiting |
NCT03832218 |
|
|
26 |
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) |
Recruiting |
NCT01694940 |
|
|
27 |
Peripheral Artery Disease: Gated P-31 Magnetic Resonance Spectroscopy in Functional Assessment of Peripheral Artery Disease (spectroAMI) |
Recruiting |
NCT03723473 |
|
|
28 |
Clinical and Molecular Manifestations of Inherited Neurological Disorders |
Recruiting |
NCT00004568 |
|
|
29 |
The Role of Nicotinamide Riboside in Mitochondrial Biogenesis |
Recruiting |
NCT03432871 |
|
|
30 |
The Development of Minimally Invasive Nanosensor Technology to Quantify Mitochondrial Function in Human Muscle |
Not yet recruiting |
NCT04086329 |
|
|
|